Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

illumina inc. - ILMN

ILMN

Close Chg Chg %
131.68 1.62 1.23%

Open Market

133.30

+1.62 (1.23%)

Volume: 545.18K

Last Updated:

Nov 21, 2024, 11:52 AM EDT

Trade Now

Company Overview: illumina inc. - ILMN

ILMN Key Data

Open

$131.19

 Day Range

130.11 - 133.72

52 Week Range

91.16 - 156.66

 Market Cap

$20.88B

Shares Outstanding

158.60M

 Public Float

157.81M

Beta

1.13

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$9.97

Yield

0.00%

 Dividend

$3.11

EX-DIVIDEND DATE

Jun 25, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

2.08M

  

ILMN Performance

1 Week
 
 -2.50%
 
1 Month
 
 -7.23%
 
3 Months
 
 0.22%
 
1 Year
 
 37.36%
 
5 Years
 
 -57.20%
 

ILMN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About illumina inc. - ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

ILMN At a Glance

Illumina, Inc.
5200 Illumina Way
San Diego, California 92122
Phone 1-858-202-4500 Revenue 4.50B
Industry Biotechnology Net Income -1,161,000,000.00
Sector Health Technology Employees 12,010
Fiscal Year-end 12 / 2024
View SEC Filings

ILMN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 4.885
Price to Book Ratio 3.854
Price to Cash Flow Ratio 46.121
Enterprise Value to EBITDA 68.662
Enterprise Value to Sales 5.153
Total Debt to Enterprise Value 0.097

ILMN Efficiency

Revenue/Employee 375,020.816
Income Per Employee -96,669.442
Receivables Turnover 5.989
Total Asset Turnover 0.403

ILMN Liquidity

Current Ratio 1.662
Quick Ratio 1.288
Cash Ratio 0.671

ILMN Profitability

Gross Margin 61.057
Operating Margin -2.087
Pretax Margin -24.80
Net Margin -25.777
Return on Assets -10.383
Return on Equity -18.811
Return on Total Capital -14.50
Return on Invested Capital -13.862

ILMN Capital Structure

Total Debt to Total Equity 39.373
Total Debt to Total Capital 28.25
Total Debt to Total Assets 22.372
Long-Term Debt to Equity 37.876
Long-Term Debt to Total Capital 27.176
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Illumina Inc. - ILMN

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
3.24B 4.53B 4.58B 4.50B
Sales Growth
-8.58% +39.73% +1.28% -1.75%
Cost of Goods Sold (COGS) incl D&A
1.02B 1.37B 1.61B 1.75B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
187.00M 251.00M 394.00M 432.00M
Depreciation
156.00M 176.00M 215.00M 235.00M
Amortization of Intangibles
31.00M 75.00M 179.00M 197.00M
COGS Growth
-5.58% +35.04% +17.49% +8.81%
Gross Income
2.22B 3.15B 2.97B 2.75B
Gross Income Growth
-9.89% +41.88% -5.77% -7.47%
Gross Profit Margin
+68.63% +69.69% +64.83% +61.06%
2020 2021 2022 2023 5-year trend
SG&A Expense
1.62B 2.87B 2.62B 2.84B
Research & Development
682.00M 1.19B 1.32B 1.33B
Other SG&A
941.00M 1.68B 1.30B 1.51B
SGA Growth
+10.11% +76.71% -8.72% +8.63%
Other Operating Expense
- - - 20.00M
-
Unusual Expense
(270.00M) 267.00M 4.65B 998.00M
EBIT after Unusual Expense
850.00M 19.00M (4.29B) (1.09B)
Non Operating Income/Expense
55.00M 926.00M (18.00M) 52.00M
Non-Operating Interest Income
- 41.00M 11.00M 58.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
49.00M 61.00M 26.00M 77.00M
Interest Expense Growth
-5.77% +24.49% -57.38% +196.15%
Gross Interest Expense
49.00M 61.00M 26.00M 77.00M
Interest Capitalized
- - - -
-
Pretax Income
856.00M 884.00M (4.34B) (1.12B)
Pretax Income Growth
-23.43% +3.27% -590.50% +74.24%
Pretax Margin
+26.43% +19.53% -94.59% -24.80%
Income Tax
200.00M 122.00M 68.00M 44.00M
Income Tax - Current - Domestic
38.00M 91.00M 16.00M 1.00M
Income Tax - Current - Foreign
45.00M 107.00M 75.00M 77.00M
Income Tax - Deferred - Domestic
124.00M (73.00M) (7.00M) (39.00M)
Income Tax - Deferred - Foreign
(7.00M) (3.00M) (16.00M) 5.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
656.00M 762.00M (4.40B) (1.16B)
Minority Interest Expense
- - - -
-
Net Income
656.00M 762.00M (4.40B) (1.16B)
Net Income Growth
-34.53% +16.16% -677.95% +73.64%
Net Margin Growth
+20.25% +16.84% -96.07% -25.78%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
656.00M 762.00M (4.40B) (1.16B)
Preferred Dividends
- - - -
-
Net Income Available to Common
656.00M 762.00M (4.40B) (1.16B)
EPS (Basic)
4.4626 5.08 -28.051 -7.3481
EPS (Basic) Growth
-34.53% +13.83% -652.19% +73.80%
Basic Shares Outstanding
147.00M 150.00M 157.00M 158.00M
EPS (Diluted)
4.4324 5.0464 -28.051 -7.3481
EPS (Diluted) Growth
-34.09% +13.85% -655.86% +73.80%
Diluted Shares Outstanding
148.00M 151.00M 157.00M 158.00M
EBITDA
767.00M 537.00M 748.00M 338.00M
EBITDA Growth
-35.06% -29.99% +39.29% -54.81%
EBITDA Margin
+23.68% +11.86% +16.32% +7.50%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 164.652
Number of Ratings 28 Current Quarters Estimate 0.915
FY Report Date 12 / 2024 Current Year's Estimate 4.12
Last Quarter’s Earnings 1.14 Median PE on CY Estimate N/A
Year Ago Earnings 0.836 Next Fiscal Year Estimate 4.429
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 21 17 16 24
Mean Estimate 0.92 1.00 4.12 4.43
High Estimates 0.96 1.12 4.15 4.70
Low Estimate 0.89 0.84 4.00 4.14
Coefficient of Variance 2.28 7.45 0.93 2.68

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 14 13
OVERWEIGHT 0 2 1
HOLD 13 10 12
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Illumina Inc. - ILMN

Date Name Shares Transaction Value
Nov 8, 2024 Carissa Rollins SVP, Chief Information Officer 11,598 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $154.96 per share 1,797,226.08
Nov 8, 2024 Scott Ericksen VP, Chief Accounting Officer 10,597 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $154.96 per share 1,642,111.12
Nov 8, 2024 Steven Barnard SVP, Chief Technology Officer 27,115 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $154.96 per share 4,201,740.40
Nov 8, 2024 Scott Davies Interim General Counsel 13,404 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $154.96 per share 2,077,083.84
Nov 8, 2024 Pat Leckman SVP, Chief People Officer 15,680 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $154.96 per share 2,429,772.80
Nov 8, 2024 Kevin Pegels Chief of Global Operations 16,357 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $154.96 per share 2,534,680.72
Aug 20, 2024 Charles E. Dadswell SVP, General Counsel 21,575 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $123.56 per share 2,665,807.00
May 23, 2024 Anna S. Richo Director 2,622 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Ankur Dhingra SVP, Chief Financial Officer 10,296 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Ankur Dhingra SVP, Chief Financial Officer 10,296 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Ankur Dhingra SVP, Chief Financial Officer 8,826 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Jakob Wedel SVP, Strategy/Corp Development 7,013 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Jakob Wedel SVP, Strategy/Corp Development 5,659 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 9, 2024 Jakob Wedel SVP, Strategy/Corp Development 5,659 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2024 Pat Leckman SVP, Chief People Officer 5,755 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2024 Pat Leckman SVP, Chief People Officer 5,755 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Jacob Thaysen Chief Executive Officer; Director 25,988 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Kathryne Reeves SVP, Chief Marketing Officer 17,965 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Charles E. Dadswell SVP, General Counsel 7,797 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 8, 2024 Joydeep Goswami SVP, Chief Financial Officer 6,497 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Illumina Inc. in the News